Johnson & Johnson (JNJ) Announces Positive Clinical Study Results for OTTAVA Robotic Surgical System

Johnson & Johnson (NYSE:JNJ) is one of the best low risk stocks to buy in 2026. On May 5, Johnson & Johnson announced positive results from the first clinical study of its investigational OTTAVA Robotic Surgical System. The findings from the prospective, multicenter FORTE study evaluating the system in Roux-en-Y gastric bypass procedures were presented at the 2026 American Society for Metabolic and Bariatric Surgery/ASMBS Annual Meeting.

In the 30-patient cohort, the study met its primary safety and performance endpoints through 30 days post-procedure, with investigators completing all surgeries robotically without converting to a non-robotic approach. The trial also showed the viability of the system’s novel architecture within space-constrained operating rooms. The system was successfully used across six hospitals, including multiple rooms historically considered too small or challenging for standard robotic setups.

digitalreflections / Shutterstock.com

Backed by these clinical and preclinical data, Johnson & Johnson (NYSE:JNJ) submitted an application to the US FDA for De Novo classification. The submission targets a general surgery indication covering multiple procedures within the upper abdomen, including gastric bypass, gastric sleeve, small bowel resection, and hiatal hernia repair.

Johnson & Johnson (NYSE:JNJ) is a global healthcare company that researches, develops, and manufactures pharmaceuticals and MedTech products. It focuses on treating complex diseases, advancing surgical care, and improving patient outcomes in areas such as cancer, immunology, and orthopedics.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.